Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
3 of 3 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Agmatine and Omega-3 have evidence — compare verdict strength side-by-side.
500-2500mg daily
Empty stomach for mood/nootropic effects, Pre-workout for pumps, Before bed for neuroprotection
Agmatine Sulfate
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
2-4 weeks
1-2 weeks
Ongoing
Acute
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Exploring the Cardiovascular Impacts of Agmatine: A Systematic Review
Medical sciences (Basel, Switzerland) (2025) · Systematic review
The effects exerted by AG depend on the dose and route of administration, as well as on the receptors involved and the pathophysiological pathway used.
Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets
Cells (2024) · Systematic review
Together, neuroinflammation and gut dysbiosis induce alterations in tryptophan metabolism, culminating in decreased serotonin synthesis, impairments in neuroplasticity-related mechanisms, and glutamate-mediated excitotoxicity.
Role of agmatine in neurodegenerative diseases and epilepsy
Frontiers in bioscience (Elite edition) (2014) · Systematic review
Agmatine, a cationic polyamine synthesized after decarboxylation of L-arginine by the enzyme arginine decarboxylase, is an endogenous neuromodulator that emerges as a potential agent to manage diverse central nervous system (CNS) disorders.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on single pilot study (n=11) showing 46% pain reduction. Very limited evidence with small sample size. GI discomfort may occur at higher doses. Individual variation noted in study.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 4/10) and wins in 3 of 3 categories.
For support mood, Omega-3 has a higher relevance score (88 vs 65).
No known interactions between Agmatine and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.